Lower-Dose transplant drug aims to tame side effects in blood cancer fight
NCT ID NCT06926595
Summary
This study is testing if a lower dose of a drug called cyclophosphamide, given after a stem cell transplant, can safely prevent a serious complication called graft-versus-host disease (GVHD) while still helping control blood cancers. It will involve 41 adults with various blood cancers who are getting a transplant from a donor. The main goal is to see how many patients are alive, free of severe GVHD, and without their cancer returning one year after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.